. home.aspx


The promise and pitfalls of molecular testing in oncology

August 30, 2019 / DR CHRIS GAJ

Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain that frustrate both physicians and patients. Central to this is how to use the large amounts of genetic data now available. Dr Chris Gaj explores the challenges and potential consequences for stakeholders in the US, Europe and emerging markets. Early targeted therapies, such as the tyrosine kinase inhibitor erlotinib from Roche/Genentech/OSI, offered the promise of precision medicine to treat cancer at a molecular level. Oncologists noted individual ‘Lazarus-like’ responses to erlotinib, but overall effectiveness was moderate in unselected populations.